De novo nucleotide biosynthetic pathway and cancer

Jie Chen; Siqi Yang; Yingge Li; Xu Ziwen; Pingfeng Zhang; Qibin Song; Yi Yao; Huadong Pei

doi:10.1016/j.gendis.2022.04.018

De novo nucleotide biosynthetic pathway and cancer

Genes Dis. 2022 May 16;10(6):2331-2338. doi: 10.1016/j.gendis.2022.04.018. eCollection 2023 Nov.

Authors

Jie Chen^{1

2}, Siqi Yang¹, Yingge Li^{1

2}, Xu Ziwen², Pingfeng Zhang¹, Qibin Song¹, Yi Yao¹, Huadong Pei²

Affiliations

¹ Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430062, China.
² Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, USA.

Abstract

De novo nucleotide biosynthetic pathway is a highly conserved and essential biochemical pathway in almost all organisms. Both purine nucleotides and pyrimidine nucleotides are necessary for cell metabolism and proliferation. Thus, the dysregulation of the de novo nucleotide biosynthetic pathway contributes to the development of many human diseases, such as cancer. It has been shown that many enzymes in this pathway are overactivated in different cancers. In this review, we summarize and update the current knowledge on the de novo nucleotide biosynthetic pathway, regulatory mechanisms, its role in tumorigenesis, and potential targeting opportunities.

Keywords: Biosynthetic pathway; Cancer; Metabolism; Nucleotide; de novo synthesis.

Publication types

Review